Articles:

Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut, and H Soreq

Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis
Mol Pharmacol 1996 50: 1423-1431. [Abstract] [PDF]  

JS Saulnier-Blache, Q Yang, JD Sherlock, and SM Lanier

Analysis of the alpha2C-adrenergic receptor gene promoter and its cell- type-specific activity
Mol Pharmacol 1996 50: 1432-1442. [Abstract] [PDF]  

M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarkozi, F Lehmann-Horn, and M Freissmuth

Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs
Mol Pharmacol 1996 50: 1443-1453. [Abstract] [PDF]  

J Zhang, AJ Watson, MR Probst, E Minehart, and O Hankinson

Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line
Mol Pharmacol 1996 50: 1454-1462. [Abstract] [PDF]  

M Cornarotti, S Tinelli, E Willmore, F Zunino, LM Fisher, CA Austin, and G Capranico

Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180)
Mol Pharmacol 1996 50: 1463-1471. [Abstract] [PDF]  

A Fujimori, M Gupta, Y Hoki, and Y Pommier

Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair
Mol Pharmacol 1996 50: 1472-1478. [Abstract] [PDF]  

DJ MacEwan and G Milligan

Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells
Mol Pharmacol 1996 50: 1479-1486. [Abstract] [PDF]  

AJ Stewart, C Pichon, L Meunier, P Midoux, M Monsigny, and AC Roche

Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine
Mol Pharmacol 1996 50: 1487-1494. [Abstract] [PDF]  

Y Xu, BA Gilbert, RR Rando, L Chen, and AH Jr Tashjian

Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs
Mol Pharmacol 1996 50: 1495-1501. [Abstract] [PDF]  

T Cihlar and MS Chen

Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells
Mol Pharmacol 1996 50: 1502-1510. [Abstract] [PDF]  

AM Andrews, B Ladenheim, CJ Epstein, JL Cadet, and DL Murphy

Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals
Mol Pharmacol 1996 50: 1511-1519. [Abstract] [PDF]  

J Magyar and G Szabo

Effects of volatile anesthetics on the G protein-regulated muscarinic potassium channel
Mol Pharmacol 1996 50: 1520-1528. [Abstract] [PDF]  

SY Yao, AM Ng, MW Ritzel, WP Gati, CE Cass, and JD Young

Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes
Mol Pharmacol 1996 50: 1529-1535. [Abstract] [PDF]  

PA Vasey, NA Jones, S Jenkins, C Dive, and R Brown

Cisplatin, camptothecin, and taxol sensitivities of cells with p53- associated multidrug resistance
Mol Pharmacol 1996 50: 1536-1540. [Abstract] [PDF]  

VI Ilyin, ER Whittemore, J Guastella, E Weber, and RM Woodward

Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol
Mol Pharmacol 1996 50: 1541-1550. [Abstract] [PDF]  

PG Bray, SR Hawley, and SA Ward

4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake
Mol Pharmacol 1996 50: 1551-1558. [Abstract] [PDF]  

PG Bray, SR Hawley, M Mungthin, and SA Ward

Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum
Mol Pharmacol 1996 50: 1559-1566. [Abstract] [PDF]  

JE Leysen, W Gommeren, L Heylen, WH Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters, and AS Lesage

Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan
Mol Pharmacol 1996 50: 1567-1580. [Abstract] [PDF]  

LL Wittmer, Y Hu, M Kalkbrenner, AS Evers, CF Zorumski, and DF Covey

Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia
Mol Pharmacol 1996 50: 1581-1586. [Abstract] [PDF]  

RA Figler, SG Graber, MA Lindorfer, H Yasuda, J Linden, and JC Garrison

Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition
Mol Pharmacol 1996 50: 1587-1595. [Abstract] [PDF]  

J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht, and M Waelbroeck

Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino- terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states
Mol Pharmacol 1996 50: 1596-1604. [Abstract] [PDF]  

TM Fong, H Yu, RR Huang, MA Cascieri, and CJ Swain

Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists
Mol Pharmacol 1996 50: 1605-1611. [Abstract] [PDF]  

KJ Reszka and CF Chignell

Acid-catalyzed oxidation of the anticancer agent mitoxantrone by nitrite ions
Mol Pharmacol 1996 50: 1612-1618. [Abstract] [PDF]  

EV Varga, X Li, D Stropova, T Zalewska, RS Landsman, RJ Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, SN Calderon, K Rice, VJ Hruby, WR Roeske, and HI Yamamura

The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists
Mol Pharmacol 1996 50: 1619-1624. [Abstract] [PDF]  

H Rauer and S Grissmer

Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3
Mol Pharmacol 1996 50: 1625-1634. [Abstract] [PDF]  

H Barbhaiya, R McClain, A Ijzerman, and SA Rivkees

Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding
Mol Pharmacol 1996 50: 1635-1642. [Abstract] [PDF]  

AO Grant, JE John, VV Nesterenko, CF Starmer, and JR Moorman

The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels
Mol Pharmacol 1996 50: 1643-1650. [Abstract] [PDF]  

TT Chiu, LY Yung, and YH Wong

Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation
Mol Pharmacol 1996 50: 1651-1657. [Abstract] [PDF]  

S Patel, S Patel, R Marwood, F Emms, D Marston, PD Leeson, NR Curtis, JJ Kulagowski, and SB Freedman

Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor
Mol Pharmacol 1996 50: 1658-1664. [Abstract] [PDF]  

CJ Price and LA Raymond

Evans blue antagonizes both alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionate and kainate receptors and modulates receptor desensitization
Mol Pharmacol 1996 50: 1665-1671. [Abstract] [PDF]  

A Nguyen, JC Kath, DC Hanson, MS Biggers, PC Canniff, CB Donovan, RJ Mather, MJ Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, GA Gutman, S Grissmer, MD Cahalan, and KG Chandy

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation
Mol Pharmacol 1996 50: 1672-1679. [Abstract] [PDF]  

JJ Krupp, B Vissel, SF Heinemann, and GL Westbrook

Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific
Mol Pharmacol 1996 50: 1680-1688. [Abstract] [PDF]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.